Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
88.95
+0.29 (0.33%)
Dec 20, 2024, 4:00 PM EST - Market closed
Boston Scientific Revenue
Boston Scientific had revenue of $4.21B in the quarter ending September 30, 2024, with 19.34% growth. This brings the company's revenue in the last twelve months to $15.91B, up 15.66% year-over-year. In the year 2023, Boston Scientific had annual revenue of $14.24B with 12.29% growth.
Revenue (ttm)
$15.91B
Revenue Growth
+15.66%
P/S Ratio
8.21
Revenue / Employee
$331,479
Employees
48,000
Market Cap
131.10B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 14.24B | 1.56B | 12.29% |
Dec 31, 2022 | 12.68B | 794.00M | 6.68% |
Dec 31, 2021 | 11.89B | 1.98B | 19.92% |
Dec 31, 2020 | 9.91B | -822.00M | -7.66% |
Dec 31, 2019 | 10.74B | 912.00M | 9.28% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pfizer | 59.38B |
Sanofi | 54.03B |
Bristol-Myers Squibb Company | 47.44B |
Medtronic | 33.00B |
Amgen | 32.53B |
Gilead Sciences | 28.30B |
Danaher | 23.74B |
Stryker | 21.97B |
BSX News
- 3 days ago - FDA classifies recall of Boston Scientific catheters as 'most serious' - Reuters
- 10 days ago - Boston Scientific CMO Discuss Solutions for Health Inequality on Today's Marketplace - PRNewsWire
- 25 days ago - The Best Large-Cap Stocks to Buy - Kiplinger
- 26 days ago - Boston Scientific Announces Agreement to Acquire Intera Oncology® Inc. - PRNewsWire
- 4 weeks ago - Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday? - Benzinga
- 5 weeks ago - Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial - PRNewsWire
- 5 weeks ago - Boston Scientific Corporation (BSX) UBS Global Healthcare Conference (Transcript) - Seeking Alpha
- 5 weeks ago - Boston Scientific Closes Acquisition of Axonics, Inc. - PRNewsWire